Galenicap
0782.712.794 · rovalta.com · 25/09/2026
Galenicap
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOGalenicap is a Private limited company incorporated in 2022. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Ixelles.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0782.712.794
- Incorporation
- 28/02/2022
- Legal form
- Private limited company
- Registered office
- Avenue Louise 65/11
1050 Ixelles · BruxellesSee on map - Contributed capital
- 1 000 996,25 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 3 filingsTrend over 3 financial years
| 2025 | 2024 | 2023 | |||
|---|---|---|---|---|---|
| Income statement | |||||
| Gross margin | -429,3 k € | -186% | -150,3 k € | +65.0% | -429,2 k € |
| EBITDA | -429,7 k € | -185% | -150,7 k € | +64.9% | -429,9 k € |
| Operating result | -495,9 k € | -136% | -210,3 k € | +53.4% | -451,7 k € |
| Net result | -533 k € | -114% | -248,7 k € | +48.0% | -478,3 k € |
| Balance sheet | |||||
| Equity | -259 k € | +64.3% | -726 k € | -52.1% | -477,3 k € |
| Total assets | 1,5 M € | +110% | 699,1 k € | +93.0% | 362,3 k € |
| Cash | 339,9 k € | +651% | 45,2 k € | -11.2% | 50,9 k € |
| Debts | 1,7 M € | +22.2% | 1,4 M € | +73.0% | 815,7 k € |
Board of directors
Source · NBB, accounts to 31/12/20253 active
Active mandates
Other companies at this address
Avenue Louise 65/11 1050 Ixelles| Company | CBE no. |
|---|---|
Bel Consco● Active | 1019.171.674 |
BTS BELGIUM● Active | 0476.980.771 |
| 1016.410.936 | |
Inclusion in Finance Europe● Active | 0803.708.148 |
ITSI Consulting● Active | 0770.776.153 |
Novus Underwriting Europe● Active | 0749.907.988 |
PROSCI BELGIUM● Active | 0536.362.389 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 28/02/2022 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 |
| Length of the financial year | 12 months | 12 months | 23 months |
| Filing date | 18/05/2026 | 07/05/2025 | 05/06/2024 |
| General meeting | 13/05/2026 | 05/05/2025 | 07/05/2024 |
| Currency of the financial year | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 3 filingsValuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20253 active
Active mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-533 k €↓
- 2024Annual accounts 2024-248,7 k €↑
- 2023Annual accounts 2023-478,3 k €
- 28/02/2022IncorporationPrivate limited company